Work

Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study.

Year: 2012

Type: article

Abstract: Result from BR. 21 study demonstrated that in unselected patients with advanced non-small cell lung cancer (NSCLC) pretreated with standard first-line or second-line chemotherapy, subsequent erlotinib treatment prolonged overall survival (OS) as compared to placebo (1). Erlotinib was evaluated as front-line therapy for unselected patients with advanced NSCLC. In a phase II study of erlotinib in NSCLC patients, Giaccone et al. (2) demonstrated a tumor response rate of 22.7% and a median overall survival of 391 days. In elderly patients treated with frontline erlotinib, the response rate was 10%, and median timeto- progression (TTP) and overall survival (OS) were 3.5 and 10.9 months respectively (3).

Source: Europe PMC (PubMed Central)

DOI: 10.3978/j.issn.2218-6751.2012.09.05

Authors: Bin-Chi Liao, James Chih-Hsin Yang

Institutions: National Taiwan University Hospital, National Taiwan University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W26965309

FWCI:

Cites: 13

Cited by:

Related to: 10